-

GILAT SATELLITE NETWORKS LTD. INVESTIGATION: GILT Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Gilat Satellite Networks Ltd. (“Gilat” or the “Company”) (NASDAQ: GILT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Gilat securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.

[LEARN MORE ABOUT POTENTIAL SECURITIES FRAUD CLAIMS]

What Happened?

On November 10, 2026, Gilat announced its third quarter 2026 financial results, reducing its fiscal year 2026 revenue guidance to $455 million to $475 million. The previous guidance of $500 million to $520 million, was reaffirmed by the Company in two Form 6-Ks filed with the SEC on May 13, 2026 and August 5, 2026. Explaining the Company’s decision to reduce its guidance, CEO Adi Sfadia stated, “Coupled with changing customer delivery and installation schedules, new orders are delayed and revenues are shifted into 2027 despite our significant order backlog. In Peru, an agreement originally expected to be signed at the first half of 2026 was signed at the end of the third quarter, shifting the associated revenues into 2027… Competitive pressure, longer decision-making process and GEO and LEO launch delays, customer delivery changes and ongoing commercial negotiations have shifted revenue timing and have affected our revenue outlook.” On this news, the price of Gilat shares declined by $1.55 per share, or approximately 20.4%, from $7.58 per share on November 9, 2026 to close at $6.03 on November 10, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Gilat securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT YOUR RIGHTS AS AN INVESTOR]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

NASDAQ:GILT

Release Versions
$Cashtags

Contacts

More News From Kirby McInerney LLP

MONTAUK RENEWABLES, INC. INVESTIGATION: MNTK Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Montauk Renewables, Inc. (“Montauk” or the “Company”) (NASDAQ: MNTK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Montauk securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.c...

BRIGHT MINDS BIOSCIENCES DRUG INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 52.3% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Bright Minds Biosciences (“Bright Minds” or the “Company”) (NASDAQ: DRUG) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 2, 2026, Bright Minds announced that the FDA had notified the Company that it...

MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 3, 2026, Madrigal disclosed in its quarterly report on Form 10-Q that, on Oc...
Back to Newsroom